Transdermal delivery system containing galantamine or salts thereof
AssigneeTaho Pharmaceuticals Ltd.
InventorsCatherine Lee, Taijung Wu
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a transdermal delivery system comprising galantamine or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of galantamine to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Alzheimer's disease. Kits including the transdermal delivery system and methods of making such delivery system are also provided.
Claims50
A transdermal delivery system which comprises a drug-containing matrix layer comprising:
- (i) galantamine or its pharmaceutically acceptable salt;
- (ii) an adhesive comprising an acrylic polymer without a functional group or an acrylate-vinyl acetate polymer having at least one carboxyl functional group (COOH);
- (iii) an enhancer composition including:
- (a) oleyl oleate and oleic acid;
- (b) oleyl oleate and propylene glycol and an antioxidant;
- or (c) a medium chain fatty acid triglyceride and an antioxidant.
A transdermal delivery system which comprises a drug-containing matrix layer comprising:
- (i) about 7-8% of galantamine or its pharmaceutically acceptable salt;
- (ii) an adhesive comprising an acrylic polymer without a functional group;
- (iii) an enhancer composition comprising:
- (a) about 10% oleic acid and about 5% oleyl oleate,
- wherein the transdermal system has a thickness of about 20-48 μm.
A transdermal delivery system which comprises a drug-containing matrix layer comprising:
- (i) about 14% of galantamine or its pharmaceutically acceptable salt;
- (ii) an adhesive comprising an acrylate-vinlyacetate polymer having at least one functional COOH group;
- (iii) an enhancer composition comprising about 10% medium chain fatty acid triglyceride;
- (iv) about 0.05% antioxidant,
- wherein the transdermal system has a thickness of about 15-45 μm.
A transdermal delivery system which comprises a drug-containing matrix layer comprising:
- (i) about 14% of galantamine or its pharmaceutically acceptable salt;
- (ii) an adhesive comprising an acrylate-vinlyacetate polymer having at least one functional COOH group;
- (iii) an enhancer composition comprising about 5% polypylene glycol and about 5% oleyl oleate;
- (iv) about 0.05% antioxidant,
- wherein the transdermal system has a thickness of about 15-45 μm.
A transdermal delivery system which comprises a drug-containing matrix layer comprising:
- (i) galantamine or its pharmaceutically acceptable salt;
- (ii) an adhesive comprising styrene butadiene-styrene block copolymer;
- (iii) an enhancer composition comprising oleyl oleate and propyleneglycol monolaurate;
- and
- (iv) an antioxidant, a solvent and an adhesive modifier.
A transdermal delivery system which comprises a drug-containing matrix layer comprising:
- (i) about 0.01-5% of galantamine or its pharmaceutically acceptable salt;
- (ii) about 60-97.7% of an adhesive comprising styrene butadiene-styrene block copolymer,
- (iii) an enhancer composition comprising about 0.1-20% oleyl oleate and about 0.1-15% propyleneglycol monolaurate;
- (v) about 0.001-0.5% of an antioxidant;
- (vi) about 0.1-20% solvent;
- and
- (vii) about 0.1-15% adhesive modifier.
Dependencies are inferred from the claim text.